SAT0133 Golimumab 3-year safety update: An analysis of pooled data from the long term extensions of randomized, double-blind, placebo-controlled studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 515.3-516 ◽  
Author(s):  
J. Kay ◽  
R. Fleischmann ◽  
E. Keystone ◽  
E.C. Hsia ◽  
M.K. Doyle ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Pooled Data

scholarly journals Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

2017 ◽  
Vol 69 (3) ◽  
pp. 347-355 ◽  
Author(s):  
Arthur Kavanaugh ◽  
Philip J. Mease ◽  
Andreas M. Reimold ◽  
Hasan Tahir ◽  
Jürgen Rech ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Term Treatment ◽  
Phase Iii ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment

scholarly journals Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies

Endocrine ◽  
2017 ◽  
Vol 60 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Rosario Pivonello ◽  
Giovanna Muscogiuri ◽  
Geoffrey Holder ◽  
Michaela Paul ◽  
Severine Sarp ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Pooled Data ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document